Dr. Falk Pharma

Company snapshot

Dr. Falk Pharma GmbH has been developing and marketing innovative medicines to treat a wide range of gastrointestinal disorders like inflammatory bowel disease or eosinophilic esophagitis as well as hepatobiliary disorders such as primary biliary cholangitis for over 60 years. As the international experts in digestive and metabolic medicine, we bring together physicians, scientists, and patients t

• 11 active pipeline program(s) linked via ClinicalTrials.gov.
• 11 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Dr. Falk Pharma. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Dr. Falk Pharma.

1. Jun 8, 2026 Clinical update

   NUC-011/BIO — Phase 1

2. Jun 8, 2026 Clinical update

   CEC-013/CEL — Phase 2

3. Jun 8, 2026 Clinical update

   BUL-5/ESD — Phase 2

4. Jun 8, 2026 Clinical update

   NAT-19/GPX — Phase 2

5. Jun 8, 2026 Clinical update

   NAT-024/BIO — Phase 1

View all clinical trial activity →

• What is Dr. Falk Pharma?

  Dr. Falk Pharma is a pharma organization headquartered in Freiburg im Breisgau, DE. Primary therapeutic focus areas include Primary Sclerosing Cholangitis (PSC), No medical condition., eosinophilic esophagitis, Celiac Disease, Idiopathic or diabetic gastroparesis. NovaPharmaNews

• Is Dr. Falk Pharma publicly traded?

  Dr. Falk Pharma appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Dr. Falk Pharma develop or market?

  We link 15 drug profile(s) where Dr. Falk Pharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/dr-falk-pharma-gmbh#company-drugs.

• What are the latest developments for Dr. Falk Pharma?

  In the last 12 months our linked public records show 11 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Dr. Falk Pharma focus on?

  Dr. Falk Pharma focuses on Primary Sclerosing Cholangitis (PSC), No medical condition., eosinophilic esophagitis based on our analysis of their pipeline programs and drug development activities.